AI Engines For more Details: Perplexity Kagi Labs You
Cardiac Effects: Xamoterol acts as a selective beta-1 adrenergic receptor agonist, meaning it primarily affects the beta-1 receptors in the heart. By stimulating these receptors, xamoterol increases the strength and efficiency of heart muscle contractions, leading to improved cardiac output and blood flow.
Treatment of Heart Failure: Xamoterol is indicated for the management of chronic heart failure, a condition characterized by the heart's inability to pump blood effectively. By enhancing cardiac contractility, xamoterol helps alleviate symptoms such as shortness of breath, fatigue, and fluid retention associated with heart failure.
Beta-Blocking Activity: Despite its beta-adrenergic agonist activity, xamoterol also exhibits some degree of beta-blocking (antagonistic) effects, particularly at higher doses. This dual mechanism of action helps to improve heart function while minimizing the risk of excessive sympathetic stimulation, which can exacerbate heart failure.
Reduction of Heart Rate: Xamoterol may decrease heart rate by inhibiting the effects of sympathetic nervous system activity on the heart. This effect can be beneficial in certain patients with heart failure who have elevated resting heart rates.
Vasodilation: Xamoterol has vasodilatory properties, meaning it relaxes and widens blood vessels. This vasodilation reduces peripheral resistance to blood flow, easing the workload on the heart and improving overall cardiovascular function.
Adverse Effects: Like all medications, xamoterol can cause side effects. Common side effects may include dizziness, headache, fatigue, nausea, and gastrointestinal disturbances. Some patients may experience bradycardia (slow heart rate) or hypotension (low blood pressure) as a result of xamoterol therapy.
Contraindications: Xamoterol is contraindicated in patients with certain cardiac conditions, including severe bradycardia, heart block, cardiogenic shock, and decompensated heart failure requiring intravenous inotropic therapy. It should not be used in patients with a history of bronchospasm or asthma due to its beta-adrenergic effects.
Monitoring: Patients receiving xamoterol therapy should be closely monitored for signs of worsening heart failure, electrolyte imbalances, and adverse drug reactions. Dosage adjustments may be necessary based on individual patient response and tolerance.
Interactions: Xamoterol may interact with other medications, particularly other cardiovascular drugs such as beta-blockers, calcium channel blockers, and antiarrhythmics. Combining xamoterol with these medications can potentiate or attenuate their effects, so careful monitoring is essential.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Akkermansia muciniphila | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Escherichia coli | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Acne | 0.2 | -0.2 | |
| ADHD | 2.2 | 0.2 | 10 |
| Age-Related Macular Degeneration and Glaucoma | 0.4 | 0.4 | |
| Allergic Rhinitis (Hay Fever) | 0.2 | 1.1 | -4.5 |
| Allergies | 2.3 | 1.5 | 0.53 |
| Allergy to milk products | 0.6 | 0.3 | 1 |
| Alopecia (Hair Loss) | 0.7 | 0.7 | |
| Alzheimer's disease | 1.6 | 2.8 | -0.75 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.6 | 0.8 | 1 |
| Ankylosing spondylitis | 1.3 | 0.6 | 1.17 |
| Anorexia Nervosa | 1.3 | -1.3 | |
| Antiphospholipid syndrome (APS) | 0.6 | 0.6 | |
| Asthma | 0.6 | 0.8 | -0.33 |
| Atherosclerosis | 0.7 | 1.2 | -0.71 |
| Atrial fibrillation | 1.7 | 0.5 | 2.4 |
| Autism | 3.1 | 3.8 | -0.23 |
| Barrett esophagus cancer | 0.2 | 0.2 | |
| benign prostatic hyperplasia | 0.1 | 0.1 | |
| Bipolar Disorder | 0.5 | 0.9 | -0.8 |
| Brain Trauma | 0.4 | 0.3 | 0.33 |
| Carcinoma | 1.9 | 1.6 | 0.19 |
| Celiac Disease | 0.8 | 2.3 | -1.87 |
| Cerebral Palsy | 0.6 | 0.9 | -0.5 |
| Chronic Fatigue Syndrome | 1.7 | 2.4 | -0.41 |
| Chronic Kidney Disease | 0.5 | 0.8 | -0.6 |
| Chronic Lyme | 0.3 | -0.3 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.2 | 0.3 | -0.5 |
| Chronic Urticaria (Hives) | 0.5 | 0.4 | 0.25 |
| Coagulation / Micro clot triggering bacteria | 0.2 | 0.8 | -3 |
| Colorectal Cancer | 1.5 | 0.5 | 2 |
| Constipation | 0.3 | 0.5 | -0.67 |
| Coronary artery disease | 0.7 | 0.5 | 0.4 |
| COVID-19 | 5.4 | 6.8 | -0.26 |
| Crohn's Disease | 2.8 | 2.8 | 0 |
| cystic fibrosis | 0.2 | 0.6 | -2 |
| deep vein thrombosis | 0.2 | 0.5 | -1.5 |
| Depression | 3.6 | 3.3 | 0.09 |
| Dermatomyositis | 0.2 | -0.2 | |
| Eczema | 0.3 | 0.3 | 0 |
| Endometriosis | 1.1 | 1 | 0.1 |
| Eosinophilic Esophagitis | 0 | 0.2 | 0 |
| Epilepsy | 1.1 | 1 | 0.1 |
| Fibromyalgia | 1 | 0.4 | 1.5 |
| Functional constipation / chronic idiopathic constipation | 1.9 | 1.2 | 0.58 |
| gallstone disease (gsd) | 1.1 | 0.4 | 1.75 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.3 | 0.5 | -0.67 |
| Generalized anxiety disorder | 0.5 | 0.7 | -0.4 |
| giant cell arteritis | 0 | 0 | |
| Graves' disease | 0.5 | 0.9 | -0.8 |
| Halitosis | 0.4 | 0.4 | |
| Hashimoto's thyroiditis | 1.3 | 0.4 | 2.25 |
| Hidradenitis Suppurativa | 0 | 0.2 | 0 |
| Histamine Issues,Mast Cell Issue, DAO Insufficiency | 1.6 | 0.5 | 2.2 |
| hypercholesterolemia (High Cholesterol) | 0.3 | 0.3 | 0 |
| hyperglycemia | 0.1 | 1 | -9 |
| Hyperlipidemia (High Blood Fats) | 0.5 | 0.2 | 1.5 |
| hypersomnia | 0.3 | -0.3 | |
| hypertension (High Blood Pressure | 1.1 | 2.6 | -1.36 |
| Hypothyroidism | 0.6 | -0.6 | |
| Hypoxia | 0.3 | 0.3 | |
| IgA nephropathy (IgAN) | 0.9 | -0.9 | |
| Inflammatory Bowel Disease | 1.3 | 3.9 | -2 |
| Insomnia | 0.4 | 0.5 | -0.25 |
| Intelligence | 0 | 0 | 0 |
| Intracranial aneurysms | 0.7 | 0.2 | 2.5 |
| Irritable Bowel Syndrome | 2.2 | 1.4 | 0.57 |
| Liver Cirrhosis | 2.2 | 1.5 | 0.47 |
| Long COVID | 2.8 | 5 | -0.79 |
| Low bone mineral density | 0.3 | -0.3 | |
| Lung Cancer | 0.4 | 1.1 | -1.75 |
| ME/CFS with IBS | 0 | 1.4 | 0 |
| ME/CFS without IBS | 0.6 | 1.1 | -0.83 |
| Menopause | 1 | 1 | |
| Metabolic Syndrome | 3.2 | 3.8 | -0.19 |
| Mood Disorders | 4.9 | 3.4 | 0.44 |
| multiple chemical sensitivity [MCS] | 0.4 | 0.3 | 0.33 |
| Multiple Sclerosis | 2.3 | 1.5 | 0.53 |
| Multiple system atrophy (MSA) | 1 | 0.8 | 0.25 |
| Neuropathy (all types) | 0.4 | 0.1 | 3 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.4 | 0.4 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.8 | 3.3 | -3.12 |
| NonCeliac Gluten Sensitivity | 0.2 | -0.2 | |
| Obesity | 4.3 | 2.1 | 1.05 |
| obsessive-compulsive disorder | 2.3 | 1.7 | 0.35 |
| Osteoarthritis | 0.5 | 0.3 | 0.67 |
| Osteoporosis | 0.9 | 0.7 | 0.29 |
| pancreatic cancer | 0.3 | 0.3 | |
| Parkinson's Disease | 1.1 | 1.7 | -0.55 |
| Polycystic ovary syndrome | 0.8 | 1.5 | -0.88 |
| Postural orthostatic tachycardia syndrome | 0 | 0.2 | 0 |
| Premenstrual dysphoric disorder | 0.6 | 0.6 | |
| primary biliary cholangitis | 0.2 | 0.2 | 0 |
| Psoriasis | 2.2 | 0.7 | 2.14 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 2.5 | 1.6 | 0.56 |
| Rosacea | 0.7 | 0.2 | 2.5 |
| Schizophrenia | 3.1 | 1 | 2.1 |
| scoliosis | 0.6 | -0.6 | |
| Sjögren syndrome | 1.3 | 1.5 | -0.15 |
| Sleep Apnea | 0.8 | 0.8 | 0 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.2 | 0.4 | -1 |
| Stress / posttraumatic stress disorder | 1.1 | 1.3 | -0.18 |
| Systemic Lupus Erythematosus | 1.2 | 1.4 | -0.17 |
| Tic Disorder | 0.6 | 0.7 | -0.17 |
| Tourette syndrome | 0.1 | 0.1 | 0 |
| Type 1 Diabetes | 1.3 | 0.9 | 0.44 |
| Type 2 Diabetes | 3.1 | 2.4 | 0.29 |
| Ulcerative colitis | 1.1 | 1.5 | -0.36 |
| Unhealthy Ageing | 1 | 1.2 | -0.2 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.